Pulmonary Medicine Clinical Trials

Clinical trials in Pulmonary Medicine provide an important step in discovering new treatments. You can browse the list of current clinical trials below to learn more.

Trials

A Multicentre, Randomised, Double[1]blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)

The study purpose is to learn more about benralizumab (the drug that will be tested in this study) to find out if it may result in an improvement of severe eosinophilic asthma and associated health problems in children.

Sponsor: AstraZeneca AB
NCT05692180 - IRB#2022-174

Learn More >

A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)

This study is being done to test the study drug, BI 1291583, for safety and side effects, when compared to a placebo, in subjects who have cystic fibrosis with bronchiectasis (CFB).

Sponsor: Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
NCT05865886 - IRB# 2023-162

Learn More >

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing

This study aims to find out if the proposed study drug, OM-85, a marketed product in several countries worldwide but not in the US yet, helps make children’s recurrent wheezing better than other drugs or other types of treatments that are currently available and approved in the US market.

Sponsor: OM Pharma SA
NCT05857930 - IRB#2023-065

Learn More >

A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose[1]Ranging Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SPR720 as Compared with Placebo for the Treatment of Patients with Mycobacterium avium Complex (MAC) Pulmonary Disease

The purpose of this study is to learn how well the study drug works compared with placebo; how safe and tolerable the study drug is compared with placebo; and to check the amount of study drug in the body.

Sponsor: Spero Therapeutics, Inc.
NCT05496374 - IRB#2023-024

Learn More >

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects with Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas aeruginosa Infection – AP-PA02-201 (Tailwind)

The main purpose of this study is to learn how well the study drug works, how long the study drug stays and works in the airway, and how safe the study drug is when taken alone (or in combination with inhaled antibiotics) compared with placebo and inhaled antibiotics alone.

Sponsor: Armata Pharmaceuticals, Inc.
NCT05616221 - IRB#2021-131

Learn More >

D3250R00107 – BURAN: Effects of Benralizumab in Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters

The aim of this study is to learn more about the drug called benralizumab (Fasenra®) and to better understand how it works in the treatment of severe eosinophilic asthma.

Sponsor: AstraZeneca
NCT05552508 - IRB#2022-107

Learn More >

Identification of Immunological Host Defense Mechanisms Against Nontuberculous Mycobacteria: A pilot Study to Measure Immune Response in Patients with and without Nontuberculous Mycobacterial (NTM) Infection

The purpose of this study is to gain insight into the factors that contribute to protection against NTM. It is hoped that information collected from this study will lead to new treatment options to improve outcomes of patients infected with NTM.

Sponsor: Grant
IRB #: 1085

Learn More >

Multicenter randomized pragmatic clinical trial comparing two-versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease

The purpose of this study is to compare the effectiveness and tolerability of a 2-study drug treatment regimen and a 3-study drug treatment regimen in subjects who have recently been diagnosed with pulmonary (lung) disease caused by Mycobacterium avium complex (MAC).

Sponsor: PCORI
IRB#: 1084

Learn More >

Bronchiectasis Registry

The purpose of the program is to identify a group of people who are interested in receiving information about research studies focused on bronchiectasis and/or non-tuberculosis mycobacteria (NTM) and possibly participating in these research studies.

Sponsor: COPD Foundation
IRB#: 872

Learn More >

CF Registry

The goal of the Patient Registry is to collect data on individuals with cystic fibrosis (CF) to better understand the illness and ultimately improve the care and survival of those with CF.

Sponsor: CFF
IRB#: 678

Learn More >

Study to Evaluate the Safety, Efficacy, and Pharmacology of ARINA-1

RVN-301 – A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacology of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough.

Sponsor: Renovion, Inc.
NCT05495243 - IRB# 2022-058

Learn More >

Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole

MACrO2 – A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with treatment-Refractory Mycobacterium avium Complex Lung Disease – Protocol EBO-301

Sponsor: AN2 Therapeutics
IRB#: 2022-029

Learn More >

Development of a nontuculous mycobaterial pulmonary disease symptom scale

Development of a nontuberculous mycobaterial pulmonary disease symptom scale

Sponsor: FDA
IRB#: 2022-011

Learn More >

Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease

PTK0796-NTM-20203 – A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety Tolerability and Pharmacokinetics of Oral Omadacycline in Treatment-Naïve Adults Subjects with Nontuberculous Mycobaacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc)

Sponsor: Paratek
NCT04922554 - IRB#2021-026

Learn More >

Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection

ENCORE 416 – A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

Sponsor: Insmed
NCT04677569

Learn More >

Qualitative Development and Psychometric Validation of a Clinical Outcome Assessment (COA) Tool

Qualitative Development and Psychometric Validation of a Clinical Outcome Assessment (COA) Tool for Bronchiectasis

Sponsor: Insmed
IRB#: 1120

Learn More >

BRONCH Study

BRONCH Study (Bronchiectasis Results Of Natural Clinical History)

Sponsor: UTHSCT
IRB#: 1116

Learn More >

Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa)

Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa) – A Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of Alvelestat (MPH996) in alpha-1 antitrypsin deficiency

Sponsor: Mereo
IRB#: 1090

Learn More >

Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections

Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections

Sponsor: Novartis
NCT04334070

Learn More >

Sponsors

Ut Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top